HEALTH CARE EQUIPMENT & SUPPLIES INDUSTRY

carmat (ALCAR:EN Paris)

Last €124.27 EUR

Change Today -0.23 / -0.18%

Volume 1.8K

ALCAR On Other Exchanges

Symbol

Exchange

ALCAR:FP

EN Paris

CXT:GR

CKMTF:US

As of 11:35 AM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

carmat (ALCAR) Snapshot

Open €125.68		Previous Close €124.50
Day High €125.68		Day Low €124.12
52 Week High 05/14/13 - €159.25		52 Week Low 07/25/12 - €90.60
Market Cap 516.7M		Average Volume 10 Days 22.0K
EPS TTM €-4.16		Shares Outstanding 4.2M
EX-Date --		P/E TM --
Dividend --		Dividend Yield --

ALCAR:FP Historical Stock Quote
ALCAR:FP Advanced Stock Chart

Related News

No related news articles were found.

carmat (ALCAR) Related Businessweek News

No Related Businessweek News Found

carmat (ALCAR) Details

Carmat Société Anonyme engages in designing and developing an implantable artificial heart. The company is developing orthotopic and biocompatible artificial heart, as well as its electrical power supply system and remote diagnosis system for patients suffering from chronic terminal heart failures. Carmat Société Anonyme was founded in 2008 and is based in Velizy Villacoublay, France.

Detailed ALCAR:FP Company Description...

www.carmatsas.com

37 Employees
Last Reported Date: 04/4/13

Founded in 2008

carmat (ALCAR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

carmat (ALCAR) Key Developments

CARMAT Obtains the Approval to Proceed with the First Human Implantations of its Bioprosthetic Artificial Heart at Four Renowned International Cardiac Surgery Centers in Four Countries

May 14 13

CARMAT announced that it has obtained the approval of four renowned international cardiac surgery centers in Belgium, Poland, Saudi Arabia and Slovenia to proceed with the first clinical implantations of its bioprosthetic total artificial heart. These institutions are the St Pierre University Hospital (Brussels, Belgium), the Silesian Center for Heart Disease (Zabrze, Poland), the Prince Sultan Cardiac Center (Riyadh, Saudi Arabia), and the University Medical Centre Ljubljana (Ljubljana, Slovenia). All these institutions share excellence in surgical results and heart patient care, depth of patient recruitment and experience in innovative medical devices pre-market clinical trials.

CARMAT SAS, Annual General Meeting, Apr 25, 2013

Mar 27 13

CARMAT SAS, Annual General Meeting, Apr 25, 2013.

CARMAT SAS Reports Earnings Results for the Year Ended December 31, 2012

Mar 4 13

CARMAT SAS reported earnings results for the year ended December 31, 2012. For the year, the company reported total operating income of €17,989 against €6,101,753 a year ago. Operating loss was €22,385,513 against €16,091,054 a year ago. Net loss was €17,189,691 against €13,441,022 a year ago. Financial profit was €110,099 against €97,271 a year ago.